Switching to Aflibercept 8 mg in Wet Age-Related Macular Degeneration That Needs Frequent Injections
Looks back at aflibercept 8 mg in adults with hard-to-control wet macular degeneration.
Plain-language title generated from the registry record
Registry title: Study of Switching to Aflibercept 8 mg in Patients With Refractory or Dependent Exudative Age-related Macular Degeneration
Key facts
- Where
- Nantes, FranceSee the site
Where in France
- CHU Nantes - Ophthalmology DepartmentNantes, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Nantes University Hospital
- Trial code
- NCT07423429
- Record updated
- 25 June 2026
- Original description
Age-related macular degeneration is a leading cause of visual impairment in older adults. In its exudative form, repeated intravitreal injections of anti-VEGF agents are required to control disease activity. A new formulation of aflibercept at a higher dose (8 mg) has been developed with the aim of extending the interval between injections.Read full original descriptionShow less
Retrospective Multicenter Real-world Observational Study of Switching to Aflibercept 8 mg in Patients With Refractory or Dependent Exudative Age-related Macular Degeneration
Age-related macular degeneration is a leading cause of visual impairment in older adults. In its exudative form, repeated intravitreal injections of anti-VEGF agents are required to control disease activity. A new formulation of aflibercept at a higher dose (8 mg) has been developed with the aim of extending the interval between injections.
This multicenter retrospective real-world observational study will evaluate the effect of switching to aflibercept 8 mg in patients with refractory or dependent exudative age-related macular degeneration. Clinical data collected during routine care will be analyzed to compare injection intervals, treatment burden, visual outcomes, anatomical outcomes, and safety before and after the switch.
Inclusion: Adults (≥18 years) with exudative (neovascular) age-related macular degeneration; Treated with intravitreal anti-VEGF therapy for more than 1 year; Switched to aflibercept 8 mg before July 31, 2025; Injection interval strictly less than 12 weeks prior to switch.
Exclusion: History of diabetic macular edema; History of uveitis; History of retinal vein occlusion (branch or central); History of pseudovitelliform macular dystrophy; High myopia (axial length > 26 mm or spherical equivalent < -6 diopters); Angioid streaks; Moderate or severe diabetic retinopathy; Patient under legal guardianship or curatorship; Pregnant or breastfeeding women.